These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32610470)

  • 1. Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
    Okura N; Asano M; Uchino J; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Fukui M; Takayama K
    J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32610470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
    Stelmachowska-Banaś M; Czajka-Oraniec I
    Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-mediated respiratory adverse events of checkpoint inhibitors.
    Tabchi S; Messier C; Blais N
    Curr Opin Oncol; 2016 Jul; 28(4):269-77. PubMed ID: 27138570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of immune related adverse events induced by immune checkpoint inhibition.
    Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
    Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.
    Liu Y; Wang H; Deng J; Sun C; He Y; Zhou C
    Transl Lung Cancer Res; 2019 Dec; 8(6):1125-1133. PubMed ID: 32010590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
    Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R
    Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
    Bourke JM; O'Sullivan M; Khattak MA
    Med J Aust; 2016 Nov; 205(9):418-424. PubMed ID: 27809739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
    Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
    Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Endocrine Dysfunction Associated with Immune Checkpoint Blockade].
    Iwama S
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):203-206. PubMed ID: 32381947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
    Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
    Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
    Choi J; Lee SY
    Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrine side effects of checkpoint inhibitors].
    Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA
    Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.